Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Lawmakers urge Biden to call out more Chinese biotech firms

Published 04/01/2024, 12:02 PM
Updated 04/01/2024, 08:36 PM
© Reuters. FILE PHOTO: US Congressman Mike Gallagher (R-WI), chairman of the House Select Committee on the Chinese Communist Party speaks as Ranking member Raja Krishnamoorthi (D-IL), looks on during a biotech science fair in Cambridge, Massachusetts, U.S., February

By Karen Freifeld

(Reuters) -A Republican and a Democratic member of Congress are calling on the Biden administration to add seven Chinese biotech firms to a list created by the Defense Department to highlight firms it says are allegedly working with Beijing's military.

In a letter dated March 29 seen by Reuters, Republican Michael Gallagher and Democrat Raja Krishnamoorthi asked Defense Secretary Lloyd Austin to take the action since Beijing could harness the power of biotechnology to strengthen its military.

"Urgent action is needed," said the lawmakers, who serve as the chairman and ranking member of the Select Committee on the Chinese Communist Party, citing risks that China could "create synthetic pathogens" to gain military advantage.

"The Department of Defense provides responses directly to members of Congress in matters of this kind," a department spokesman said in a statement. "We have no additional information or further details to release at this time."

A spokesperson for the Chinese Embassy in Washington said "some people" in the United States should stop suppressing Chinese companies under false pretexts.

"When it comes to 'using biotech to strengthen its military,' the U.S. side should reflect on itself, rather than groundlessly attacking and smearing China," the spokesperson, Liu Pengyu, said in a statement.

The letter is the latest sign of growing concern in Washington about China's biotech sector.

The U.S. Congress is considering legislation to bar federal agencies from contracting with China's BGI and WuXi AppTec, among others, as part of an effort to keep China from accessing American genetic data and personal health information.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

U.S. intelligence officials in late February told senators working on the bill that Chinese pharmaceutical firm WuXi AppTec had transferred U.S. intellectual property to Beijing without consent, Reuters reported.

Being placed on the Pentagon's Chinese military-backed companies list doesn't involve immediate bans. However, it can be a blow to companies' reputations and represents a warning to U.S. firms considering doing business with them. It could also put pressure on the Treasury Department to sanction them.

In their letter, Gallagher and Krishnamoorthi call for the addition of Innomics and STOmics, which they allege are subsidiaries of BGI. BGI Genomics Co, a publicly listed subsidiary of BGI Group, was added to the list in 2022.

Reuters reported in 2021 that BGI has made sales worldwide of prenatal tests developed in collaboration with China's military and has used them to collect genetic data from millions of women for sweeping research on traits of populations.

BGI has said it is not controlled by the Chinese government or military and that it respects human rights.

The letter also names Origincell, for allegedly operating a bio-storage cell tank and having ties to the Chinese military and Vazyme Biotech, which allegedly makes bioactive compounds and has investors with ties to the military.

"STOmics Americas is a U.S.-based company that has no operations in China nor any connections whatsoever with the Chinese military," the BGI Group said in a statement.

The other companies did not immediately respond to requests for comment.

Lawmakers in February asked that WuXi AppTec be considered for the list. The company has said it poses no national security risk to any country. It also has said it is not aware of any unauthorized transfers of any U.S. client's IP to China.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Once again we see the US government moving too slow and too late. Credit to the CCP for taking advantage; they play western politicians and western governments like a violin.
It's totally absurd. Chinese companies in their own country can't work for the Chinese government in military area? So, US companies in US also can't workfor US military? So laughable what US is doing: double standard abs have no shame. We hate communism but we love Vietnam. We hate autocracy but at love Saudi Arabia. Think about it.
it's about maintaining advantages over potential enemy. like or not, we're in cold war again, and as history teaches us america won't stop here until either it prevails or china is destroyed. from now until then i don't think nobody cares about optics :)
The Chinese Government is in control of the United States government at the moment.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.